{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026809","form_type":"8-K","ticker":null,"cik":"0001069308","company_name":"Acer Therapeutics Inc.","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.846055+00:00","generated_at":"2026-06-14T05:35:26.379507+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acer Therapeutics faces Nasdaq delisting risk from bid price and MVLS deficiencies","bullets":["Received bid price deficiency notice June 5, 2023; must close at $1.00+ for 10 consecutive business days by Dec 4, 2023.","Received MVLS deficiency notice May 3, 2023; MVLS must be $35M+ for 10 consecutive business days by Oct 30, 2023.","May also cure MVLS deficiency by meeting minimum stockholders' equity of $2.5 million.","If not cured by deadlines, eligible for additional 180-day bid price cure period or delisting appeal."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026809","json":"https://secwatch.observer/filing/0000950170-23-026809.json","markdown":"https://secwatch.observer/filing/0000950170-23-026809.md","text":"https://secwatch.observer/filing/0000950170-23-026809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069308/000095017023026809/0000950170-23-026809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069308/000095017023026809/acer-20230605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:35:26.379507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75e7e4f9a6bfe2ce438d27ea967d530002fafbf8","claim":"Acer Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 5, 2023, Acer Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market under","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069308/000095017023026809/0000950170-23-026809-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}